Nuvalent’s stock jumps 22% after ESMO 2024 – what’s next for this biotech game-changer?
Nuvalent, Inc., a biopharmaceutical company specialising in targeted cancer therapies, has seen its stock price skyrocket following the release of compelling data from two clinical ... Read More
Genentech’s Alecensa shows promise in Phase III ALINA study for early-stage ALK-positive NSCLC
Genentech, a Roche Group member, has announced positive results from its Phase III ALINA study evaluating Alecensa (alectinib), setting a new standard for treating early-stage ... Read More